Home/Filings/4/0001437749-20-003695
4//SEC Filing

DARGAN CHARLES K 4

Accession 0001437749-20-003695

CIK 0000880242other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 1:06 PM ET

Size

21.0 KB

Accession

0001437749-20-003695

Insider Transaction Report

Form 4
Period: 2020-01-31
DARGAN CHARLES K
Chief Financial Officer
Transactions
  • Other

    Option to Purchase Common Stock

    2020-02-0160,0003,029,000 total
    Exercise: $0.57From: 2010-02-01Exp: 2020-02-01Common stock (60,000 underlying)
  • Award

    Option to Purchase Common Stock

    2020-02-25+27,5003,056,500 total
    Exercise: $0.21From: 2020-02-25Exp: 2030-02-25Common stock (27,500 underlying)
  • Other

    Option to Purchase Common Stock

    2020-01-3110,0003,089,000 total
    Exercise: $0.50From: 2010-01-31Exp: 2020-01-31Common stock (10,000 underlying)
  • Award

    Option to Purchase Common Stock

    2020-02-25+400,0003,456,500 total
    Exercise: $0.21From: 2020-02-25Exp: 2030-02-25Common stock (400,000 underlying)
Footnotes (5)
  • [F1]This transaction reports the expiration, without exercise, of an Option to purchase common stock issued by Issuer to Reporting Person.
  • [F2]This Option was originally issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer during the time period specific in the Engagement Agreement between the Reporting Person and the Issuer in effect on the date the Option was issued.
  • [F3]This Option was issued to Reporting Person to replace options to purchase 110,000 shares that had been issued as sole compensation to the provision of services to the Issuer and had expired, unexercised.
  • [F4]The Option is exercisable according to its vesting schedule: (i) 75,000 shares as of December 31, 2019, and then (ii) in equal monthly installments of 25,000 shares beginning January 31, 2020, so long as the Engagement Extension Agreement dated February 25, 2020, between Reporting Owner and Issuer, remains in force and effect.
  • [F5]This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from October 1, 2019 through January 31, 2021.

Issuer

BIOLARGO, INC.

CIK 0000880242

Entity typeother

Related Parties

1
  • filerCIK 0001112799

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 1:06 PM ET
Size
21.0 KB